美股A股
StockGist
Back
10-K/A2026-04-29· deepseek-chat

ELTX · Elicio Therapeutics, Inc.

0001601485-26-000035

SEC filing

Summary

FY2025 was a transformative year for Elicio, marked by significant insider financing and conversion of debt to equity, but the company remains pre-revenue with ongoing operating losses.

Full analysis

Insider Financing and Capital Structure

Executive Compensation and Leadership

Director Compensation and Ownership

Audit and Equity Plans

Related Party Transactions

Related party transactions were primarily with GKCC, the director-controlled entity, including the convertible note conversion and promissory note issuance. These transactions were conducted on terms that management believes are fair to the company, though they highlight the company's dependence on insider financing.